Gland Pharma Q3 Results | Net profit, margin up; revenue dips 10%

Drug firm Gland Pharma Ltd on Monday (February 3) reported a 6.7% year-on-year (YoY) increase in net profit at ₹204.7 crore for the third quarter that ended December 31, 2024. In the corresponding quarter of the previous fiscal, the company posted a net profit of ₹191.9 crore.CompanyValueChange%ChangeRevenue from operations fell 10.4% to ₹1,384 crore against ₹1,545.2 crore year-on-year.At the operating level, EBITDA was up 1% to ₹360 crore over ₹356.4 crore in Q3 FY24. The EBITDA margin stood at 26% in the reporting quarter versus 23.1% in the corresponding period last fiscal. EBITDA is earnings before interest, tax, depreciation, and amortisation.Also Read: Thyrocare Technologies Q3 Results | Net profit, revenue show healthy growthGland Pharma launched 13 new molecules during Q3 FY25, including chlorpromazine, dexamethasone, phenylephrine, phytonadione, and diphenhydramine. The company also filed four ANDAs (abbreviated new drug applications) and received approvals for eight during the quarter.Its cumulative US ANDA filings now stand at 366, with 312 approvals and 54 pending. Global product registrations have reached 1,736. R&D expenses for the quarter stood at ₹437 million, accounting for 4.3% of revenue.Gland Pharma received establishment inspection reports (EIRs) from the FDA for its Dundigal and Pashamylaram facilities in Hyderabad, confirming the successful closure of recent inspections. The company incurred a total capital expenditure of ₹1,379 million during the quarter ended December 31, 2024.Also Read: Gateway Distriparks Q3 Results | Net profit rockets 7-fold to ₹456 crore, declares dividendCenexi’s Fontenay site in Paris faced production disruptions due to an unannounced inspection by ANSM, the French health authority. However, the site’s new high-capacity ampoule line began production as scheduled, increasing ampoule manufacturing capacity by 40-50 million units, which is expected to enhance customer service. Cenexi, a European contract development and manufacturing organisation (CDMO), was acquired by Gland Pharma.At the Hérouville site in Normandy, commercial production of a new inactivated vaccine and an ophthalmic gel commenced in December 2024, with a gradual scale-up planned for 2025. Additionally, Cenexi is installing a new pre-filled syringe line, expected to be operational later this year, which will significantly expand capacity to meet growing demand.The Braine-l’Alleud site in Belgium continued to face production setbacks due to a lyophilizer (a freeze dryer) breakdown reported last quarter. Production levels are expected to be restored in H1 FY26. Cenexi remains focused on achieving positive EBITDA in the next fiscal year, supported by revenue growth exceeding the €200-million mark.Also Read: Alembic Pharma Q3 Results | Net profit declines 23% to ₹138 crore, net sales up 4%The results came after the close of the market hours. Shares of Gland Pharma Ltd ended at ₹1,512.15, down by ₹16.55, or 1.08%, on the BSE.(Edited by : Shoma Bhattacharjee)First Published: Feb 3, 2025 6:19 PM IST

Source link